JLMediLabs utilizes single-molecule techniques for pan-cancer early detection from a single blood draw, providing a sensitive and rapid diagnostic solution. This approach addresses the challenge of late-stage cancer diagnosis by enabling earlier intervention through a minimally invasive method.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer diagnostic methods often detect the disease at later stages, reducing treatment options and survival rates. Traditional diagnostic procedures can be invasive, expensive, and time-consuming, hindering early and frequent screening.
Solution
JLMediLabs offers a novel approach to pan-cancer early detection using single-molecule analysis performed on a single blood draw. This minimally invasive liquid biopsy technique enables the identification of cancer biomarkers at their earliest stages, even before symptoms appear. By detecting cancer signals with high sensitivity and specificity, JLMediLabs aims to facilitate earlier intervention and improve patient outcomes. The technology provides a rapid and cost-effective diagnostic solution, making frequent cancer screening more accessible.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and individuals seeking proactive cancer screening.
Features
- Single-molecule analysis for enhanced sensitivity in biomarker detection
- Minimally invasive blood draw procedure
- Pan-cancer detection capability
- Rapid turnaround time for diagnostic results
- Cost-effective screening solution